Atossa Therapeutics Inc expected to post a loss of $1.08 a share - Earnings Preview

Atossa Therapeutics

07/08/2026 16:58

Atossa Therapeutics Inc ATOS.OQ ATOS.O is expected to  show no change in quarterly revenue when it reports  results on August 7 for the period ending September 30 2026

​LSEG's mean analyst estimate for Atossa Therapeutics Inc is for a loss of $1.08 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts had risen by about 7.7% in the last three months. ​
Wall Street's median 12-month price target for Atossa Therapeutics Inc is $22.00, about 809.1% above its last closing price of $2.42
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-1.03
-1.02
-0.95
Beat
7.3
Mar. 31 2026
-1.02
-6.12
-1.11
Beat
81.9
Dec. 31 2025
-1.20
-1.14
-3.08
Missed
-170.8​
Sep. 30 2025
-1.01
-1.00
-1.05
Missed
-5
​​Jun. 30 2025
-0.75
-0.86
-1.05
Missed
-21.7
Mar. 31 2025
-0.82
-0.85
-0.75
Beat
11.8​
Dec. 31 2024
-0.95
-0.75
Beat
21
Sep. 30 2024
-0.75
-0.85
-0.90
Missed
-5.9
This summary was machine generated August 7 at 15:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)